ストックスクリーナーアプリを入手
0.8057
38.91%
0.2257
プレマーケット:
.80
-0.0057
-0.71%
前日終値:
$0.58
開ける：
$0.6015
24時間の取引高:
7.72M
Relative Volume:
2.43
時価総額：
$137.41M
収益：
-
当期純損益:
$-101.17M
株価収益率:
-0.7747
EPS:
-1.04
ネットキャッシュフロー:
$-96.57M
1週間 パフォーマンス:
+32.67%
1か月 パフォーマンス:
+128.70%
6か月 パフォーマンス:
-19.43%
1年 パフォーマンス:
-4.38%
1日の値動き範囲:
$0.60
$0.8423
1週間の範囲:
$0.5293
$0.8423
52週間の値動き範囲:
$0.2612
$1.60
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
名前
X 4 Pharmaceuticals Inc
セクター
電話
857-529-8300
住所
61 NORTH BEACON STREET, BOSTON, MA
XFOR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
0.8057 | 137.41M | 0 | -101.17M | -96.57M | -0.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.65 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.68 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
632.04 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.50 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.77 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-12-12 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 再開されました | B. Riley Securities | Buy |
| 2022-12-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | ROTH Capital | Buy |
| 2019-12-09 | アップグレード | Citigroup | Neutral → Buy |
| 2019-12-05 | 開始されました | B. Riley FBR | Buy |
| 2019-06-07 | 開始されました | Stifel | Buy |
| 2019-06-05 | 開始されました | Cowen | Outperform |
すべてを表示
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4) - Quantisnow
How To Check Senores Pharmaceuticals IPO Allotment Status? Find Latest GMP, Listing Date And More - NDTV Profit
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected - Simply Wall St
Senores Pharmaceuticals IPO oversubscribed 93.69 times; check allotment and listing details - Zee Business
Senores Pharmaceuticals IPO Day 3 Highlights: Issue booked 93.41 times on third day; check GMP & other details | Stock Market News - Mint
Senores Pharmaceuticals IPO: Issue subscribed 93 times on last day; here’s how to check allotment status - Upstox
Layoff Tracker: Stubborn Layoff Trend Continues Across Biopharma in 2024 - BioSpace
5 Companies That Celebrated First Approvals in 2024 - BioSpace
XTX Topco Ltd Raises Holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Grace Therapeutics And 2 Other US Penny Stocks Worth Watching - Simply Wall St
Top 10 pharma companies in India by market cap [2024] - Forbes India
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet - Quantisnow
Global Antibody Drug Conjugates Market Set For 23.4% Growth, Reaching $24.8 Billion By 2028 - EIN News
FDA Tracker: FDA Hands Out Atopic Dermatitis Approvals to Galderma, Organon - BioSpace
Verition Fund Management LLC Buys Shares of 44,355 X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Granules India gets USFDA nod for generic drug - The Economic Times
Granules India gets US regulator FDA's approval for generic ADHD drug - Business Standard
Global Pharmaceutical Cartridges Market Set For 9.9% Growth, Reaching $3.29 Billion By 2028 - EIN News
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346) - Marketscreener.com
Global Nanopharmaceuticals Market Set For 17.0% Growth, Reaching $183.89 Billion By 2028 - EIN News
Companies partner to advance X-ray crystallography in early drug discovery - European Pharmaceutical Manufacturer
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End - Eagle-Tribune
What is Duloxetine? Antidepressant Drug Recalled by FDA - Newsweek
OliX Pharmaceuticals, Inc (KOSDAQ:226950) Looks Just Right With A 34% Price Jump - Simply Wall St
Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 - The Manila Times
Universe Pharmaceuticals stock hits 52-week low at $1.66 - Investing.com
Phanes Therapeutics' PT217 granted Fast Track Designation by the FDA for NEPC - PR Newswire
X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition - The Manila Times
Sony Group Corporation (NYSE:SONY): A Bullish Investment Perspective - Yahoo Finance
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth - BioSpace
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS - PR Newswire
B.C. can sue opioid providers for health-care costs on behalf of other governments, Canada's top court rules - CBC News
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire
SEC Form 4 filed by CEO, President Rodriguez Raul R - Quantisnow
X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. - PR Newswire
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Two Smaller Companies Worthy of Your "Attention" - Yahoo Finance
Global X-ray Photoelectron Spectroscopy Market to Reach USD - GlobeNewswire
7 Companies Owned by Pfizer - Investopedia
x4 pharmaceuticals, inc. Earnings dates - RTTNews
Lexicon Pharmaceuticals to lay off 60% of workforce after FDA setback - Reuters.com
FDA approves cancer drug developed by B.C.'s Zymeworks - Business in Vancouver
Atenolol Global Market 2024 – Top Manufacturers, Latest Trends, Future Prospects And Outlook By 2033 - WhaTech
B. Riley Predicts Increased Earnings for X4 Pharmaceuticals - Defense World
Spotlight On 3 US Penny Stocks With At Least $60M Market Cap - Simply Wall St
B. Riley Expects Stronger Earnings for X4 Pharmaceuticals - MarketBeat
Benzodiazepine Drugs Market Overview: Industry Insights, Demand Trends, Competitive Landscape, and Key Inno... - WhaTech
X 4 Pharmaceuticals Inc (XFOR) 財務データ
収益
当期純利益
現金流量
EPS
0.50%
1.47%
大文字化:
|
ボリューム (24 時間):